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Current next-generation sequencing (NGS) technologies allow unprecedented insights into the
mutational profiles of tumors. Recent studies in myeloproliferative neoplasms have further dem-
onstrated that, not only the mutational profile, but also the order in which these mutations are
acquired is relevant for our understanding of the disease. Our ability to assign mutation order
from NGS data alone is, however, limited. Here, we present a strategy of highly multiplexed
genotyping of burst forming unit-erythroid colonies based on NGS results to assess subclonal
tumor structure. This allowed for the generation of complex clonal hierarchies and determi-
nation of order of mutation acquisition far more accurately than was possible from NGS data
alone. © 2018 ISEH – Society for Hematology and Stem Cells. Published by Elsevier Inc. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Next-generation sequencing (NGS) methods have provided
unprecedented insights into the somatic mutations
associated with hematological malignancies, including my-
eloproliferative neoplasms (MPNs) [1–3]. However, although
we are now able to acquire detailed lists of mutations present
in tumors at a given state of development, we are only be-
ginning to understand how these mutations are associated in
tumor subclones and the history of mutation acquisition during
tumor development. The relevance of analyzing the makeup
of tumors in detail has been demonstrated recently in studies
of MPN patients and have shown, for the first time in any
cancer, that the order in which somatic mutations are ac-
quired influences tumor biology and clinical presentation [4,5].
However, determining the subclonal architecture of tumors
accurately remains challenging. In particular, mutant allele
burdens determined by NGS have a limited ability to predict
the clonal landscape and clonal history within a patient. Clonal
analysis of hematopoietic colonies provides a powerful ap-
proach to circumvent the problems associated with sequencing
pooled cell populations [1,2,4,5]. Here, we present our strat-
egy to determine complex subclonal tumor structures using
a combination of NGS and highly multiplexed genotyping
of burst forming unit-erythroid colonies (BFU-Es).
Methods
Clustering analysis
Clustering was carried out using MClust Version 3 for R [6] on the
basis of NGS-derived mutational allele burden data for patient
PD4772. MClust utilizes normal mixture modeling for univariate
data to classify the allele burdens into clusters as a prediction for
the subclonal structure of the tumor.
Blood acquisition and processing
Patient PD4772 was recruited from Addenbrookes Hospital after
written informed consent and ethical approval consistent with the
Declaration of Helsinki. As described previously [4], mono-
nuclear cells (MNCs) were isolated from 40 mL of peripheral blood
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using a sodium diatrizoate/polysaccharide density gradient
(Lymphoprep; Axis Shield PLC, Oslo, Norway) according to the
manufacturer’s instructions. MNCs were plated at a density of 1 × 106
cells/mL in MethoCult H4034 (StemCell Technologies, Vancou-
ver, Canada). BFU-Es were identified and picked into 100 µL of
PBS before vigorous pipetting to break the colony apart. Of the
100 µL cell suspension, 10 µL was used for capillary sequencing
and 10 µL for Fluidigm SNP genotyping.
Fluidigm SNP genotyping
Fluidigm SNP genotyping was performed according to the manu-
facturer’s instructions (SNP Genotyping User Guide, PN
68000098 M2, Appendix C: SNP Type Assays for SNP Genotyping
on the 192.24 Dynamic Array Integrated Fluidics Circuit, IFC).
Briefly, SNPType genotyping assays were designed for all muta-
tions identified previously in patient PD4772 by NGS according to
the manufacturer’s recommendations and ordered from Fluidigm
(Supplementary Table E1, online only, available at www.exphem.org).
Predefined regions of DNA were amplified using polymerase chain
reaction (PCR) with specific target amplification primers for 22 cycles
before a 1:100 dilution of the amplified products was prepared. The
diluted amplified product was loaded onto the 192.24 Dynamic Array
IFC for SNP Genotyping (BMK-M-192.24GT, Fluidigm) along-
side a sample premixture including ROX reference dye and real-
time master mixture. Assays were composed of allele-specific primers
tagged with either FAM or HEX and an untagged common locus-
specific PCR primer. The array was processed using the BioMark
system (Fluidigm), which performs the thermal cycling and image
acquisition.
Data were analyzed using the Biomark SNP Genotyping Anal-
ysis software version 3.1.2 to obtain genotype calls. Briefly, the
software calculates the relative fluorescence intensities of FAM and
HEX compared with the background ROX signal, classifying each
of the data points into one of three genotypes (wild-type, hetero-
zygous mutant, or homozygous mutant) using k-means based
clustering methods.
Capillary sequencing
Capillary sequencing was carried out as described in Ortmann et al
[4]. Sequences of the primers used in this study are provided
in Supplementary Table E2 (online only, available from
www.exphem.org).
Results/discussion
Whole-exome sequencing of bulk granulocyte DNA from poly-
cythemia vera patient PD4772 revealed 16 somatic mutations
with a range of mutant allele burdens (Supplementary
Table E1, online only, available from www.exphem.org [1]).
We set out to determine the subclonal tumor composition in
this patient from a comparison of mutant allele burdens alone
by means of a clustering analysis (Fig. 1). The result of this
analysis revealed two separate clusters of mutations indicat-
ing the presence of two tumor subclones. The JAK2V617F
mutation had the highest allele burden (46.9%), defining cluster
1 (Fig. 1). The second cluster contained the remainder of all
other mutations, where allele burdens ranged from 5.4% to
23.6% (cluster 2, Fig. 1). Although the algorithm was not able
to determine further clusters given the wide range of mutant
allele burdens within cluster 2, we hypothesized a more
complex subclonal makeup of this tumor. Given the relatively
low allele burdens, a potential serial acquisition of two mu-
tations cannot be distinguished from a biclonal acquisition
using analysis that is based on allele burden alone. More-
over, the analysis did not provide insights in the historical
development of the tumor.
In order to gain a more comprehensive understanding of
this patient’s tumor, we analyzed 176 BFU-E colonies that
were cultured from peripheral-blood-derived mononuclear
cells. Each of these colonies originated from a single blood
progenitor cell. Genotyping each colony therefore provides
information of the genetic makeup of the tumor at single-
cell resolution. The combined interpretation of genotypes from
a large number of individual colonies allows conclusions to
be drawn about the subclonal composition of the tumor.
To genotype simultaneously and efficiently a large number
of BFU-E colonies, for all 16 mutations identified, we es-
tablished a multiplexed assay based on custom SNP genotyping
technology provided by Fluidigm. Firstly, we compared the
performance of Fluidigm multiplexed SNP genotyping with
classical capillary sequencing by genotyping a subset of 96
colonies for five mutations with both technologies. Fluidigm
SNP genotyping returned a genotype in 476 of the 480
genotyping reactions (96 colonies × 5 mutations, an average
call rate of 99.1%). In contrast, capillary sequencing re-
sulted in a total call rate of 409/480 or 85.2% (Fig. 2). The
genotyping results were then compared using only those colo-
nies for which both methods yielded a genotype. On average,
87.7% of reactions returned concordant calls between the two
methods (range 81.5–95.6%) (Fig. 2). Given the increased
time efficiency with which multiplexed genotyping can be
performed and the higher genotyping call rates, in addition
Figure 1. Prediction of clonal structure from mutant allele burden alone for
patient PD4772. Predicted mutant allele burdens from whole-exome se-
quencing were visualized using the MClust classification plot. Each line
represents a mutation shown both as part of the two identified clusters (red
and blue) and combined (black). Cluster 1 is defined only by the JAK2V617F
mutation and all other mutations are found in cluster 2.
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to the considerable overlap in results compared with capil-
lary sequencing, we decided to use multiplexed genotyping
assays to genotype BFU-E colonies.
All 176 colonies from patient PD4772 were then genotyped
for all 16 mutations using Fluidigm SNP genotyping. To best
assess the order of mutation acquisition, the results were com-
piled in a tabular format to show the particular genotype (wild-
type, heterozygous, or homozygous) for a specific mutation
for a specific colony (Fig. 3A). The columns (genes) were
ordered based on the frequency of the mutation in the 176
colonies so that the gene showing highest overall mutant allele
burden is on the left. Colonies in rows are ordered to gen-
erate clusters of colonies with the same genotype (Fig. 3, nodes
i–viii). The clusters represent genetically defined subclones
of the tumor and the number of colonies within each cluster
reflects the relative size of the respective subclone. Two colo-
nies of a similar genotype were required as a minimum to
call a separate cluster. When only one colony showed a certain
mutational profile (which occurred in 34 of the 176
genotyped), the colony was removed from the analysis. Finally,
all of the clusters were reordered so that the order of acqui-
sition of subclones was readily visible.
These data were then converted into a clonal hierarchy
(Fig. 3B). Within the hierarchy, each node represents a ge-
netically defined subclone. Lines between nodes reflect the
evolutionary relationship of subclones so that a more re-
cently established subclone is connected to the clone from
which it arose. Genetically, such a subclone carries all of the
mutations of the parental clone and any newly acquired
mutations.
Our results demonstrate that there is an unrecognized com-
plexity to the subclonal architecture of the patient’s tumor
clone. After the initial mutation acquisition, JAK2V617F (Fig. 3B,
node ii), two independent subclones (Fig. 3B, nodes iii and
v), which were identified by two distinct subsets of muta-
tions, arose from the same parental tumor clone with the
JAK2V617F mutation. Within node iii, additional mutations
weare acquired sequentially (Fig. 3B, node iv). After the ac-
quisition of KSR2c.2582+7G>T, an additional bifurcation of the
hierarchy occurred, with two sets of mutations acquired se-
quentially within the JAK2V617F/KSR2c.2582+7G>T clone (vi and
vii/viii).
Previous studies in MPNs have shown that mutational data
from NGS alone can only be used to call mutation order in
under half of cases [4,5]. In the case of low mutant allele
burden, it is also not possible to tell whether mutations are
acquired in a linear or biclonal fashion from NGS data alone.
Here, we showed that combining NGS with highly multi-
plexed genotyping of BFU-E colonies is one method that can
accurately determine the subclonal structure of a tumor. We
could determine a highly complex subclonal structure, showing
both the linear and biclonal acquisition of mutations, which
was far more complex than the structure predicted from mutant
allele burdens alone.
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Figure 2. Multiplexed SNP genotyping is an efficient method for genotyping BFU-E colonies. Number of colonies for which a genotype could be called out
of 96 colonies for each mutation is shown. Five genes were genotyped by capillary sequencing and multiplexed SNP genotyping. Shaded regions highlight
the number of colonies for which the same genotype was called by both technologies.
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Figure 3. Schematic representation of the subclonal structure and evolution of the tumor for patient PD4772. Wild-type colonies with no mutations are shown
in peach and heterozygous mutations are shown in blue. No colonies with homozygous mutations were identified in this patient. Each individual cluster of
colonies representing a single subclone is highlighted by a Roman numeral and the number of colonies within the subclone. (A) Row-wise representation of
the mutational status of each colony for each mutation. Each row is one colony and each column is one gene. Red lines delineate clusters of colonies with
the same mutational characteristics. (B) Clonal hierarchy derived from the data in (A). A node further down the hierarchy includes all mutations that precede
it on the branch.
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Supplementary data
Table E1.
Gene Protein Change DNA Change Chr Position NGS allele burden (%)
JAK2 p.V617F c.1849G>T 9 5073770 46.9
CPN2 p.V292F c.874G>T 3 194062558 21.3
HADHA p.R291Q c.872G>A 2 26437358 21.5
CHEK2 p.E231D c.693A>T 22 29120993 16.3
SETD1A p.Y382C c.1145A>G 16 30976208 14.8
POLR2F p.R154R c.462G>T 22 38437084 23.6
KSR2 p.? c.2582+7G>T 12 117914262 20.5
ZFP161 p.N409N c.1227C>T 18 5290980 18.8
BAI3 p.E1391V c.4172A>T 6 70071337 16.1
SLC24A1 p.E492E c.1476G>A 15 65917894 14.7
RNF19B p.I573R c.1718T>G 1 33404025 13.3
UPF2 p.T531A c.1591A>G 10 12043738 13
KCNMA1 p.A220G c.659C>G 10 78944618 10.7
LRRC67 p.G203R c.607G>A 8 67900698 10.5
TTC3L p.V1299V c.3897T>C 21 38538413 7.1
UNC45B p.? c.1547+6G>T 17 33496956 5.4
Mutations, mutation locations and allele burdens for all mutations found by exome sequencing for patient PD4772 [1]. p., protein; p.?, splice site
mutation; c., cDNA; Chr, chromosome; NGS, next generation sequencing. Genomic coordinates are from the hg19 reference genome.
Table E2.
Gene Protein Change DNA Change Chr Position Forward Primer Reverse Primer
JAK2 p.V617F c.1849G>T 9 5073770 CAAGCAGCA
AGTATGAT
GAGCAAGC
CTGACACC
TAGCTGTG
ATCCTGAA
CPN2 p.V292F c.874G>T 3 194062558 TGGGAGGT
GGGTAATG
GCATTGTA
TCCATCTT
TGCCTCCC
TGGGTAAT
HADHA p.R291Q c.872G>A 2 26437358 TGGTCCAG
AATGGCAA
TAAGGAGGA
ACAGAATT
GACAGCGTA
TGCCATGA
CHEK2 p.E231D c.693A>T 22 29120993 CACGCCCA
GCAACTTA
CTCATCTT
GAAGATCA
CAGTGGCAA
TGGAACC
SETD1A p.Y382C c.1145A>G 16 30976208 CTCCTCAT
TGTCCTCG
TCCTCCTC
AGGAGGTG
TAAGAAGGT
GGGAAGC
Mutation locations and primer details used for capillary sequencing. p., Protein; c., cDNA; Chr, chromosome. Genomic coordinates are from the hg19
reference genome.
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